|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, we conducted a prospective study of the relationship between oophorectomy and the risk of contralateral breast cancer in 1781 BRCA1 and 503 BRCA2 mutation carriers with breast cancer.
|
30756284 |
2019 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Strong associations with CBC were found for carrying a BRCA1 (RR = 3.7; 95%CI:2.8-4.9), BRCA2 (RR = 2.8; 95%CI:1.8-4.3) or CHEK2 c.1100delC (RR = 2.7; 95%CI:2.0-3.7) mutation.
|
30580169 |
2019 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For contralateral breast cancer, the cumulative risk 20 years after breast cancer diagnosis was 40% (95% CI, 35%-45%) for BRCA1 and 26% (95% CI, 20%-33%) for BRCA2 carriers (hazard ratio [HR] for comparing BRCA2 vs BRCA1, 0.62; 95% CI, 0.47-0.82; P=.001 for difference).
|
28632866 |
2017 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 carriers and non-carriers developed contralateral breast cancer at an earlier age than BRCA2 carriers.
|
27726213 |
2017 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Age at diagnosis of the first breast cancer was a significant predictor of CBC risk in BRCA1/2 mutation carriers only; those diagnosed before age 41 years had a 10-year cumulative CBC risk of 23.9% (BRCA1: 25.5%; BRCA2: 17.2%) compared with 12.6% (BRCA1: 15.6%; BRCA2: 7.2%) for those 41 to 49 years of age (P = .02); our review of published studies showed ranges of 24% to 31% before age 40 years (BRCA1: 24% to 32%; BRCA2:17% to 29%) and 8% to 21% after 40 years (BRCA1: 11% to 52%; BRCA2: 7% to 18%), respectively.
|
26700119 |
2016 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It can reasonably be offered to breast cancer patients with BRCA1 or BRCA2 mutation for the prevention of CBC.
|
26022977 |
2015 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
|
26467044 |
2015 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.
|
26239694 |
2015 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
|
24951267 |
2014 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The cumulative 5-years risk of CBC for BRCA1 and BRCA2 mutation carriers was 15% (95% CI: 9.5%-20%) and 9% (95% CI: 5%-14%), respectively.
|
25467311 |
2014 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Stratification by BRCA1/BRCA2 mutation status showed that the occurrence of contralateral breast cancer was 8-fold higher among mutation carriers compared with non-carriers.
|
24519389 |
2014 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Young women with breast cancer who have a family history of breast cancer and who test negative for deleterious mutations in BRCA1 and BRCA2 are at significantly greater risk of CBC than other breast cancer survivors.
|
23269995 |
2013 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For BRCA2 carriers, the corresponding risks were 55% (95% CI = 41% to 70%) for breast cancer, 16.5% (95% CI = 7.5% to 34%) for ovarian cancer, and 62% (95% CI = 44% to 79.5%) for contralateral breast cancer.
|
23628597 |
2013 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.
|
23165859 |
2013 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 or BRCA2 mutation carriers more accurately perceived their risk for contralateral breast cancer, whereas women without a known mutation substantially overestimated this risk.
|
24042365 |
2013 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined whether the risk of CBC associated with radiation treatment was higher among women with germline BRCA1/BRCA2 mutations than among non-carriers.
|
23706288 |
2013 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After left truncating at recruitment to the cohort, adjusted HR estimates were 0.58 (95% CI, 0.29 to 1.13) and 0.48 (95% CI, 0.22 to 1.05) based on 657 BRCA1 and 426 BRCA2 mutation carriers with 100 CBCs over 4,392 person-years of prospective follow-up.
|
23918944 |
2013 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ER-status of the first breast cancer was predictive of ER-status of asynchronous contralateral breast cancer (P = 0.0004 for BRCA1; P = 0.002 for BRCA2).
|
22144499 |
2012 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The cumulative risk of contralateral breast cancer 25 years after first breast cancer was 44.1% (95%CI, 37.6% to 50.6%) for patients from BRCA1 positive families, 33.5% (95%CI, 22.4% to 44.7%) for patients from BRCA2 positive families and 17.2% (95%CI, 14.5% to 19.9%) for patients from families that tested negative for BRCA1/2 mutations.
|
23216834 |
2012 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The 15-year actuarial risk of contralateral breast cancer was 36.1% for women with a BRCA1 mutation and was 28.5% for women with a BRCA2 mutation.
|
21487411 |
2011 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status.
|
21161372 |
2011 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this article, we present one approach to this problem, hierarchical statistical modeling of data observed in a case-control study of contralateral breast cancer (CBC) in which all the participants were genotyped for variants in BRCA1 and BRCA2.
|
21520273 |
2011 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Women with a BRCA1 or BRCA2 mutation have an elevated risk of breast cancer and of contralateral breast cancer.
|
21221768 |
2011 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.
|
19597986 |
2010 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study.
|
20130978 |
2010 |